Advocacy intelligence hub — real-time data for patient organizations
GIANCARLO FATOBENE — PHASE2
Sichuan University — PHASE2
Henry Ford Health System — PHASE1
Hospital Israelita Albert Einstein — PHASE2, PHASE3
Busulfex: FDA approved
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.
Digibind: FDA approved
Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Digibind
Glaxo Wellcome Inc.
Patient Assistance Programs1
Busulfex
Otsuka Pharmaceutical Company, Ltd
Busulfex
(Busulfan)Orphan drugOtsuka Pharmaceutical Company, Ltd
Alkylating Drug [EPC]
12.1 Mechanism of Action Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a fo...
Digibind
(Digoxin immune FAB (Ovine))Orphan drugGlaxo Wellcome Inc.